For & Against

What's Next

NexgenRx runs on a metronomic disclosure cadence: Q1 results in mid-May, Q2 in mid-August, Q3 in mid-to-late November, FY in late March; semi-annual dividend declarations in April and August (with an occasional December top-up). There is no analyst coverage, no consensus, and no guidance — so each quarterly print is itself the catalyst. The next 3–6 months pivot on one specific test: does 1Q26 operating margin clear 10% (Bull's confirmation) or fall below 8% (Bear's trigger)?

No Results

What the market will watch most closely. The May 15 Q1 print is the single number that resolves the entire For/Against debate. FY2025 printed four straight quarters of positive operating income for the first time in the dataset; the Bear's whole case is that this is the third such breakout in five years and the prior two reverted within twelve months. A clean Q1 print above 10% tips toward "structural"; under 8% snaps the multiple back to "FY25 was 2021 again." Embedded in the same release is dividend coverage — with FY2025 dividends at 1.01x net income, any quarterly earnings dip mechanically pushes the trailing payout ratio over 100%.

Two slower-burning watch items. The AGM in mid-June and the late-September anniversary of the FY24 board reshuffle are both windows where management could name a successor / President / COO. Loucks is 22 years in role with no named #2 — the Bear's "key-man + governance" point only resolves if management explicitly names succession; silence keeps the discount intact. Separately, any strategic tuck-in or take-out signal from TELUS Health, GreenShield, ClaimSecure, or People Corporation would prove out the entire independent-TPA franchise value — no dated window, but the Bull names this as the asymmetric upside while the Bear names insurer-captive underpricing as the symmetric downside.

There are no regulatory windows, no covenant tests (zero long-term debt), no patent cliffs, and no pending litigation in the public record. The catalyst calendar is genuinely thin — three earnings prints, one AGM, two dividend declarations. That is the whole list.

For / Against / My View

For

**1. FY2025 was a step-change in cash generation, not noise.** Free cash flow jumped to C$4.63M from C$0.83M the prior year — a 5.5x increase against only 8.8% revenue growth — and net income, operating income, and EBITDA all moved in the same direction in the same year. Operating income was positive in all four quarters of FY2025 for the first time in the dataset.

Evidence: FY2025 FCF C$4.63M vs FY2024 C$0.83M; quarterly operating income C$0.55M / C$0.34M / C$0.61M / C$0.74M across 1Q–4Q25; FY2025 EBITDA C$3.18M vs FY2024 C$2.32M.

**2. Trading at 6.5x P/FCF and 8.1x EV/EBITDA on a recurring-revenue SaaS.** Market cap of C$30M against C$4.6M of FY2025 FCF puts the stock at a 6.5x P/FCF multiple, and EV/EBITDA of 8.1x sits 39% below its own 10-year mean of 13.3x — for a business with 83% gross margins, zero long-term debt, and C$4.78M of cash (16% of market cap).

Evidence: P/E TTM 28.6, EV/EBITDA current 8.1x vs 10y mean 13.3x; P/S 1.7x vs 5y mean 1.6x; C$4.78M cash and zero debt; 83.3% gross margin, 17.8% EBITDA margin.

**3. Toll-booth economics, proven through three recessions.** NexgenRx adjudicated roughly C$1B of claims in 2025 against C$17.9M of its own revenue — a 55x ratio that defines a payment-rail toll, not a balance-sheet risk. Revenue grew in every recession year measured (+16% in 2008, +23% in 2015, +16% in 2020) because PEPM admin fees on benefit plans are non-discretionary spend.

Evidence: C$1B claims adjudicated / C$17.9M revenue = 55x; revenue +16% in GFC 2008, +23% in oil-shock 2015, +16% in COVID 2020.

Bull Price Target (C$)

0.60

Timeline (months)

Methodology: 12x EV/EBITDA on C$3.5M FY2026E EBITDA = C$42M EV + C$5M net cash = C$47M equity / 71.1M shares = C$0.66; cross-checked against 2.5x P/S on C$19.5M FY2026E revenue (the FY2021 peak multiple). Discounted to C$0.60 for liquidity. Disconfirming signal: 1Q26 operating margin below 5% on flat-to-down revenue.

Against

**1. Margins flip sign every other year — FY25 is noise, not regime.** Operating margin has reversed sign **eight times in twenty years**, and the last three pre-FY25 prints were 2.3%, -1.0%, and 7.3%. A bull paying for the FY25 12.5% operating margin is paying for the *third* margin breakout in five years that the prior two reverted within twelve months.

Evidence: margins_20y: FY2020 19.5% → FY2022 2.3% → FY2023 -1.0% → FY2024 7.3% → FY2025 12.5%. Quant Predictability score 1/5. FY2022-24 EBITDA range C$1.0-2.3M after FY2021 print of C$3.4M — the exact same setup as today.

**2. The 100% dividend payout is a confession, not a reward.** FY2025 dividends of **C$1.30M on net income of C$1.29M = 1.01x payout ratio**. A genuinely scaling vertical SaaS reinvests at 30%+ ROIC; NexgenRx returns essentially everything because there is nothing to reinvest in at this scale. The dividend is what management does *because* organic growth has decelerated from FY2024's +19% to FY2025's +8.8%.

Evidence: Dividends C$1.30M FY25 on net income C$1.29M; Sherlock alignment table flagging "Capital allocation tension"; Story tab — FY24 +19% to FY25 +8.8% deceleration.

**3. Already a commodity multiple — no margin of safety to "rerate higher".** Current 1.7x P/S sits **above** the 5-year mean of 1.6x. The market-implied Quant Fair Value is **C$0.35 — 10% below the C$0.39 spot.** Compress the multiple back to the 5-year P/S mean of 1.6x on a normalized C$2M EBITDA (the four-year average, not the FY25 spike) and the math gives C$0.22.

Evidence: val_kpis: P/S 5y mean 1.62 vs current 1.72; fv_range: Bear C$0.22, Base C$0.35; FY2022-2025 EBITDA average ~C$2.1M.

Bear Downside (C$)

0.22

Timeline (months)

Trigger: Q1 or Q2 FY26 operating margin reverts below 8%. Cover signal: Two consecutive quarters of 12%+ operating margin AND a named successor / President with a defined transition timeline — both required, neither alone is sufficient.

The Tensions

1. Is FY2025 a regime change or the third margin breakout that reverts?

Bull says FY2025 was a step-change — four consecutive positive operating-income quarters for the first time in the dataset, FCF up 5.5x against 8.8% revenue growth, EBITDA C$3.18M vs C$2.32M. Bear says it is the third such breakout in five years (FY2020 19.5% margin and FY2021 18%+ both reverted to sub-2% within twelve months) and the Quant Predictability score of 1 of 5 prices in exactly that pattern. Both cite the same margins_20y series and the same FY2025 12.5% operating margin. This resolves on the May 15 Q1 FY26 print: above 10% operating margin confirms structural; below 8% confirms reversion. There is a single number on a single date that ends this fight.

2. The 100% dividend payout — capital discipline or capacity confession?

Bull reads C$1.30M of dividends with C$5M net cash and 1% four-year dilution as a founder-owner refusing to destroy capital — Loucks holds 10.5% of common, so a buyback-and-dividend mix matches what an aligned operator should do at sub-scale. Bear reads the identical 1.01x payout ratio as a structural admission that there is nothing to reinvest in at C$18M revenue, and that the insider-heavy register (37% of common) is the actual beneficiary. Both cite FY2025 dividends C$1.30M against net income C$1.29M. This resolves on the next two quarterly prints' organic-growth line — if FY2024's 19% growth re-emerges, the Bull's "discipline" reading wins; if FY2025's 8.8% deceleration extends, the Bear's "capacity confession" reading wins.

3. Insider concentration — alignment or entrenchment?

Bull cites Loucks's 10.48% common + 13.79% preferred plus his May 2024 open-market buy of 120,000 shares at C$0.28 as proof a founder-owner is eating his own cooking. Bear cites the same insider register (37% of common across the top four holders) plus the May 2024 Majority Voting event — where director Charles Burns was effectively voted off and quietly re-appointed 21 weeks later — as proof the cap structure is captured and shareholder votes do not stick. Both point to the 22-year Loucks tenure with no named successor. This resolves on either the AGM (mid-June) or a late-September board statement — a publicly named President / COO / successor defuses the Bear; another year of silence with the preferred class still opaque on SEDAR+ entrenches the Bull's read into the discount.

My View

I lean cautious here, with a slight edge to the Against side — but the case is genuinely close and the resolving signal is unusually clean. The For side has the better arithmetic (6.5x P/FCF, zero debt, 16% cash-to-cap, recurring SaaS through three recessions); the Against side has the better track record (eight margin sign-flips in twenty years, two prior breakouts that fully reverted, a 1/5 Predictability score that exists for exactly this reason). What tips it for me is Tension #1: the May 15 Q1 print is binary, and the Bear's pattern-match is too specific to dismiss — paying 8.1x EV/EBITDA on the third breakout in five years is paying for a regime change that historically has not happened. I would wait for the May 15 print rather than chase here. The condition that flips my view: Q1 FY26 operating margin clears 10% on revenue at or above C$4.5M. That single data point — not the price target, not the dividend, not the insider buy — is the only thing that makes this a structural compounder rather than the fourth chapter of a 20-year sawtooth.